A few weeks ago, the FDA approved a costly Alzheimer’s drug developed by Biogen, but for what benefit?
1. There is not strong evidence that Amyloid beta plaques causes Alzheimer’s disease, even if aducanumab showed a reduction in those plaques.
2. Aducanumab did not show any real-life outcomes like improvement in cognitive outcomes or reduction in mortality.
もっと詳しく
